MIND IDE Trial of Penumbra’s Artemis Neuro Evacuation Device Shows Potential Promise for Patients Experiencing Hemorrhagic Stroke

The MIND Trial, sponsored by Penumbra, set out to explore whether minimally invasive surgery with the Artemis Neuro Evacuation Device could improve outcomes in patients with primarily deep and lobar intracerebral hemorrhages. Due to early stoppage, the MIND study’s data was unable to demonstrate a difference in the primary endpoint, modified Rankin scores at 180 days. However, exploratory analysis revealed that the Artemis Neuro Evacuation Device showed significant improvement for patients with moderate to large volume supratentorial intracerebral hemorrhage (ICH) at 30 days, compared to medical management alone, for both deep and lobar hemorrhages.

The data was presented at the International Stroke Conference in Los Angeles on Feb. 5, 2025, by Dr. David Fiorella, MD, PhD, director of the Cerebrovascular Center at Stony Brook University Hospital and at the World Intercranial Hemorrhage Conference in Sydney Australia on March 28, 2025 by Dr. Christopher Kellner, MD, a cerebrovascular neurosurgeon at the Mt. Sinai Health System in New York.

According to the American Heart Association, intracerebral hemorrhages are the deadliest form of acute stroke, with early mortality ranging between 30% to 40%.¹ The Artemis Neuro Evacuation Device is a minimally invasive surgical tool that uses neuro-navigation and an endoscope to visualize and evacuate hemorrhages through a 19 F endoscopic sheath, offering effective hematoma removal while minimizing injury to surrounding brain tissue.

The MIND IDE study, a multicenter, open-label, randomized trial of patients with moderate to large supratentorial ICH, found that patients who underwent minimally invasive surgery with Artemis saw a reduction in ICH volume of 81.5% in the deep cohort, and 80.4% in the lobar cohort. The researchers also noted improvements in symptomatic perihematomal edema and modified Rankin scores at 30 days. Fewer patients were intubated at 30 days if they underwent minimally invasive surgery with Artemis compared to the medical management group.

However, the primary endpoint of 180-day global disability did not show a difference in modified Rankin scores between the two groups.

“Our data suggests that minimally invasive surgery is effective at eliminating or reducing early reversible intracerebral hemorrhage damage,” said Dr. Fiorella, MD, PhD. “The Artemis procedure remains a viable option, particularly for patients with deep intracerebral hemorrhage, for reducing disability at 30 days and getting patients out of the ICU or hospital earlier.”

Enrollment for the MIND IDE study was stopped early after the ENRICH trial demonstrated that minimally invasive surgery improves functional outcomes in patients with superficial ICH at 180 days and equipoise was lost for patients with lobar hemorrhages.

About Penumbra

Penumbra Inc., the world’s leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Its broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.

Important Safety Information

Product availability varies by country. Additional information about Penumbra’s products can be located on Penumbra’s website at https://www.penumbrainc.com/products/artemis-neuro-evacuation-device/. Caution: Federal (USA) law restricts these devices to sale by or on the order of a physician. Prior to use, please refer to Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use. Risk information can be found at peninc.info/risk.

1. American Heart Association. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage. May 17, 2022. Accessed February 3, 2025.